Immunic, Inc.

Stage 4 · Declining · week 1⚠ 3→4 today

As of Oct 22, 2026, Immunic is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $7.22, 57.3% below its 52-week high and below its 200-day average, which is rising.

$7.22

-4.50% today

$98.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is IMUX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 19w

S2 27w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 2w → S4 14w → S1 12w → S4 2w → S1 5w → S4 10w → S1 1w → S2 1w → S1 1w → S2 13w → S3 4w → S4 14w → S1 8w → S4 13w → S1 8w → S4 19w → S1 3w → S2 27w → S3 5w → S4 1w current

Total tracked: 166 weeks across 21 stage runs.

IMUX among Biotechnology221st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…221	IMUXImmunic, Inc.	Stage 4 · wk 1	45	−22.9%

vs 52W High

-57.3%

$5.10 lo$16.90 hi

57.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-37.1%

200 DMA: $11.47 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.32x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-22.9%

-46.1%

-21.4%

YTD

+23.8%

-12.2%

Scan Membership

Breakout Watch

Latest: 2024-08-09

9 appearances in last 60 days. First seen: 2019-06-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S43→4

Wk 1 · Vol 1.32x

2026-10-21S3

Wk 6 · Vol 0.93x

2026-10-20S3

Wk 5 · Vol 1.23x

2026-10-19S3

Wk 5 · Vol 0.92x

2026-10-16S3

Wk 5 · Vol 1.07x

2026-10-15S3

Wk 5 · Vol 0.83x

2026-10-14S3

Wk 5 · Vol 1.30x

2026-10-13S3

Wk 4 · Vol 1.74x

2026-10-12S3

Wk 4 · Vol 0.46x

2026-10-09S3

Wk 4 · Vol 1.59x

2026-10-08S3

Wk 4 · Vol 1.89x

2026-10-07S3

Wk 4 · Vol 1.25x

Moving averages & range

50 DMA

$11.30

200 DMA

$11.47

52W High

$16.90

52W Low

$5.10

5D Low

$6.97

Resistance levels (recent highs)

20d High

$9.51

60d High

$16.90

120d High

$16.90

250d High

$16.90

Next resistance

+31.7%

to 20d High

ROE

-138.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.8

Immunic: quick answers

What stage is Immunic in?

As of Oct 22, 2026, Immunic (IMUX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Immunic in an uptrend?

No. Immunic is in a Stage 4 downtrend. It trades 37.1% below its 200-day average, which is rising.

How far is Immunic from its 52-week high?

Immunic closed at $7.22 on Oct 22, 2026, 57.3% below its 52-week high of $16.90. Its 52-week low is $5.10.

How has Immunic performed over the past year?

As of Oct 22, 2026, Immunic is down 12.2% over the past year and up 23.8% so far in 2026.

Which sector and industry is Immunic in?

Immunic is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.